Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRIDEX CORPIRIX · Entity 7882 | Director | June 13, 2025 | June 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRIDEX CORP
Report date June 13, 2025 · Filed June 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2032-06-13 | Direct | 53,000 |
Reported balance
After 2025-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-13 · Grant · Acquired 53,000 · Balance 53,000 F1: This option was granted pursuant to the Company's 2008 Equity Incentive Plan, as amended, and is exempt pursuant to Rule16b-3. F2: All shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the Company's 2026 annual meeting of stockholders. |
| Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2032-06-13 | Direct | 15,000 |
Reported balance
After 2025-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-13 · Grant · Acquired 15,000 · Balance 15,000 F1: This option was granted pursuant to the Company's 2008 Equity Incentive Plan, as amended, and is exempt pursuant to Rule16b-3. F3: The shares are subject to vesting according to the following schedule: 1/48 of the total number of shares subject to the option shall vest on July 13, 2025, and each month thereafter, such that the option shall be fully vested on the earlier of (i) the four-year anniversary of the grant date or (ii) the Company's 2029 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted pursuant to the Company's 2008 Equity Incentive Plan, as amended, and is exempt pursuant to Rule16b-3.
F2: All shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the Company's 2026 annual meeting of stockholders.
F3: The shares are subject to vesting according to the following schedule: 1/48 of the total number of shares subject to the option shall vest on July 13, 2025, and each month thereafter, such that the option shall be fully vested on the earlier of (i) the four-year anniversary of the grant date or (ii) the Company's 2029 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2025 Filed Jun 25, 2025 00:21 UTC | IRIDEX CORP IRIX · Entity 7882 | GrantCommon Stock (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0000950170-25-089703 · ownership.xml · derivative · entry 2 Chen Yu-Hao · CIK 0002061835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-13 F1 · security: This option was granted pursuant to the Company's 2008 Equity Incentive Plan, as amended, and is exempt pursuant to Rule16b-3. F3 · derivative.exercise_date: The shares are subject to vesting according to the following schedule: 1/48 of the total number of shares subject to the option shall vest on July 13, 2025, and each month thereafter, such that the option shall be fully vested on the earlier of (i) the four-year anniversary of the grant date or (ii) the Company's 2029 annual meeting of stockholders. Read SEC document |
| June 13, 2025 Filed Jun 25, 2025 00:21 UTC | IRIDEX CORP IRIX · Entity 7882 | GrantCommon Stock (right to buy) · Derivative | 53,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0000950170-25-089703 · ownership.xml · derivative · entry 1 Chen Yu-Hao · CIK 0002061835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2032-06-13 F1 · security: This option was granted pursuant to the Company's 2008 Equity Incentive Plan, as amended, and is exempt pursuant to Rule16b-3. F2 · derivative.exercise_date: All shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the Company's 2026 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.